Synthesis of 18F-labelled 2-(4′-fluorophenyl)-1,3-benzothiazole and evaluation as amyloid imaging agent in comparison with [11C]PIB

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 3, 2009, Pages 602-605

  Serdons, K ^a   Verduyckt, T ^a   Vanderghinste, D ^b   Cleynhens, J ^a   Borghgraef, P ^c   Vermaelen, P ^b   Terwinghe, C ^b   Leuven, F Van ^c   Laere, K Van ^b   Kung, H ^d   Bormans, G ^a   Verbruggen, A ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

2 Phenylbenzothiazole; Alzheimer; Amyloid; Fluor 18; PIB

Indexed keywords

2 (4' FLUOROPHENYL) 1,3 BENZOTHIAZOLE F 18; 6 HYDROXY 2 (4' N METHYLAMINOPHENYL) 1,3 BENZOTHIAZOLE C 11; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; NITRO DERIVATIVE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 2 (4' FLUOROPHENYL) 1,3 BENZOTHIAZOLE; 2-(4'-FLUOROPHENYL)-1,3-BENZOTHIAZOLE; AMYLOID; BENZOTHIAZOLE; BENZOTHIAZOLE DERIVATIVE; FLUORINE;

ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; BINDING COMPETITION; BRAIN HOMOGENATE; BRAIN SLICE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG SCREENING; DRUG SYNTHESIS; DRUG UPTAKE; FLUORESCENCE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; QUANTUM YIELD; RADIOCHEMISTRY; SENILE PLAQUE; TRANSGENIC MOUSE; ANIMAL; CHEMICAL MODEL; CHEMISTRY; DRUG DESIGN; GENETICS; KINETICS; METABOLISM; METHODOLOGY; SYNTHESIS; TEMPERATURE; TISSUE DISTRIBUTION;

MUS;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BENZOTHIAZOLES; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; FLUORINE RADIOISOTOPES; HUMANS; KINETICS; MICE; MICE, TRANSGENIC; MODELS, CHEMICAL; TEMPERATURE; TISSUE DISTRIBUTION;

EID: 58849137648     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.12.069     Document Type: Article

References (25)

1. Selkoe D.J. Physiol. Rev. 81 (2001) 741
2. Blennow K., de Leon M., and Zetterberg H. Lancet 368 (2006) 387
3. Furumoto S., Okamura N., Iwata R., Yanai K., Arai H., and Kudo Y. Curr. Top. Med. Chem. 7 (2007) 1773
4. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D., Bergström M., Savitcheva I., Huang G., Estrada S., Ausén B., Debnath M., Barletta J., Price J.C., Sandell J., Lopresti B., Wall A., Koivisto P., Antoni G., Mathis C., and Langström B. Ann. Neurol. 55 (2004) 306
5. Mathis C., Lopresti B., Mason N., Price J., Flatt N., Bi W., Ziolko S., DeKosky S., and Klunk W. J. Nucl. Med. 48 (2007) 56P
6. Shi D.-F., Bradshaw T.D., Wrigley S., McCall C.J., Lelieveld P., Fichtner I., and Stevens M.F.G. J. Med. Chem. 39 (1996) 3375
7. Mathis C.A., Bacskai B.J., Kajdasz S.T., McLellan M.E., Frosch M.P., Hyman B.T., Holt D.P., Wang Y., Huang G.-F., Debnathd M.L., and Klunk W.E. Bioorg. Med. Chem. Lett. 12 (2002) 295
8. +). Formic acid was added to enhance electrospray ionisation. The drift of the mass spectrometer was corrected by co-injection of a compound with known mass. After acquisition of the data with Masslynx software (version 3.5), the spectrum was corrected using this compound as lock mass.
9. 2S 257.0379). Mp 226.1-227.4 °C.
10. 10NFS 230.2856). Mp 97.2-98.5 °C.
11. Kamal A., Ahmed S.K., Reddy K.S., Khan M.N.A., Shetty R.V., Siddhardha B., Murty U.S.N., China A., and Nagaraja V. Lett. Drug Des. Discov. 4 (2007) 550
12. Mu X.-J., Zou J.-P., Zeng R.-S., and Wu J.-C. Tetrahedron Lett. 46 (2005) 4345
13. 18F]2 = 28.5 min).
14. Kilbourn M.R. Fluorine-18 Labeling of Radiopharmaceuticals. Nuclear Science Series (1990), National Academy Press, Washington, DC
15. Serdons K., Terwinghe C., Vermaelen P., Kung H., Bormans G., and Verbruggen A. J. Nucl. Med. 47 (2006) 31P
16. Chitneni S.K., Serdons K., Evens N., Fonge H., Celen S., Deroose C.M., Debyzer Z., Mortelmans M., Verbruggen A.M., and Bormans G.M. J. Chromatogr. A 1189 (2007) 323
17. Kung M.P., Hou C., Zhuang Z.P., Skovronsky D., and Kung H.F. Brain Res. 1025 (2004) 89
18. All animal experiments were approved by the local Ethical Committee.
19. Vibratome sections (40 μm) of the brain of transgenic mice overexpressing human APP (amyloid precursor protein) were incubated for 1 h at room temperature with the non-radioactive compound 2 at a concentration of 1 μM. After incubation, the sections were rinsed with tap water and treated with 0.2% NaOH in 80% ethanol to reduce background staining. The slices were rinsed again with tap water and coverslipped using a Mowiol-DABCO solution. For immunohistochemical staining, the same vibratome sections were treated with a 0.1% Triton X-100 solution in PBS (PBST) and 10% foetal calf serum to block non-specific binding. The slices were subsequently incubated overnight with the amyloid-binding monoclonal antibody AβN25 (Oncogene Research Products, San Diego, CA, USA) which stains both dense and fibrillar plaques. The sections were treated again with PBST and rinsed with PBS before fixation with Mowiol-DABCO solution. Fluorescence microscopy was performed using a Leica DMR microscope equipped with a digital Leica DC480 camera and a UV filter set with following specifications: excitation: 340-380 nm bandpass filter, dichromatic mirror 400 nm; emission: 425 nm longpass filter. The images were collected and processed with Leica IM500 image processing software.
20. Serdons K., Verduyckt T., Cleynhens J., Bormans G., and Verbruggen A. J. Label. Compd. Radiopharm. 51 (2008) 357
21. Dishino D., Welch M., Kilbourn M., and Raichle M. J. Nucl. Med. 24 (1983) 1030
22. ® (fentanyl citrate 63 μg/ml and fluanisone 2 mg/ml). The mice were sacrificed by decapitation at 2 or 60 min pi. Blood was collected in a tared tube and weighed. All organs and other body parts were dissected and weighed, and their radioactivity was counted in a gamma counter. Results were corrected for background radioactivity and are expressed as percentage of the injected dose (% ID) or as percentage of the injected dose per gram tissue (% ID/g). For calculation of total radioactivity in blood, blood mass was assumed to be 7% of the total body mass.
23. 11C]PIB, respectively (1 week interval).
24. Klunk W.E., Lopresti B.J., Ikonomovic M.D., Lefterov I.M., Koldamova R.P., Abrahamson E.E., Debnath M.L., Holt D.P., Huang G.-F., Shao L., DeKosky S.T., Price J.C., and Mathis C.A. J. Neurosci. 25 (2005) 10598
25. Toyama H., Ye D., Ichise M., Liow J.-S., Cai L., Jacobowitz D., Musachio J.L., Hong J., Crescenzo M., Tipre D., Lu J.-Q., Zoghbi S., Vines D.C., Seidel J., Katada K., Green M.V., Pike V.W., Cohen R.M., and Innis R.B. Eur. J. Nucl. Med. Mol. Imaging 32 (2005) 593